Bayer / Monsanto Merger (EU)

Farmers depend on a few global companies for seeds engineered to resist pests and herbicides designed to match. Bayer's crop-science division and Monsanto were two of the biggest players worldwide.

The merger would combine Monsanto's seed genetics and Roundup-linked traits with Bayer's crop protection chemicals and research pipeline—vertical and horizontal overlap regulators could not ignore.

The European Commission opened an in-depth investigation, focusing on herbicide-seed bundles, trait licensing, and innovation in digital farming tools that recommend planting and spraying decisions.

Clearance came with one of the largest remedy packages in agribusiness history: BASF bought businesses spanning cotton, canola, soybean seeds, vegetable seeds, glufosinate herbicides, and digital assets.

US and other jurisdictions imposed additional conditions, but the EU process drove much of the structural relief.

Bayer later faced separate litigation over Roundup product liability—not part of the merger case but shaping public perception of the combined firm.

For competition analysts, Bayer/Monsanto shows how 'big ag' consolidation is managed through surgical divestitures rather than outright prohibition.

Seed and chemical mergers affect global food supply chains.

Structural remedies try to recreate a rival overnight via asset sales.

Farmers face fewer independent suppliers after the wave of ag mergers.

Merger would reduce competition in seeds and non-selective herbicides.

Innovation in traits and digital ag would slow.

Farmers would face higher prices and worse licensing terms.

Bayer argued the deal improved R&D scale and sustainable farming tools.

It said remedies preserved competition while enabling needed investment.

Agricultural input prices ripple into food costs—even urban consumers feel indirect effects.

Remedy buyers like BASF must actually compete, not just hold assets passively.